Literature DB >> 24206138

Antibody-based imaging of HER-2: moving into the clinic.

R E Wang1, Y Zhang, L Tian, W Cai, J Cai.   

Abstract

Human epidermal growth factor receptor-2 (HER-2) mediates a number of important cellular activities, and is up-regulated in a diverse set of cancer cell lines, especially breast cancer. Accordingly, HER-2 has been regarded as a common drug target in cancer therapy. Antibodies can serve as ideal candidates for targeted tumor imaging and drug delivery, due to their inherent affinity and specificity. Advanced by the development of a wide variety of imaging techniques, antibody-based imaging of HER-2 can allow for early detection and localization of tumors, as well as monitoring of drug delivery and tissue's response to drug treatment. In this review article, antibody-based imaging of HER-2 are summarized and discussed, with an emphasis on the involved imaging methods.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24206138      PMCID: PMC3852915          DOI: 10.2174/1566524013666131111120951

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  152 in total

Review 1.  Monoclonal antibodies as innovative therapeutics.

Authors:  Janice M Reichert
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

2.  Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

Authors:  Tove Olafsen; Vania E Kenanova; Gobalakrishnan Sundaresan; Anne-Line Anderson; Desiree Crow; Paul J Yazaki; Lin Li; Michael F Press; Sanjiv S Gambhir; Lawrence E Williams; Jeffrey Y C Wong; Andrew A Raubitschek; John E Shively; Anna M Wu
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.

Authors:  C E Kotts; F M Su; C Leddy; T Dodd; S Scates; M R Shalaby; C M Wirth; D Giltinan; R W Schroff; A R Fritzberg; H M Shepard; D J Slamon; B M Hutchins
Journal:  Cancer Biother Radiopharm       Date:  1996-04       Impact factor: 3.099

4.  Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.

Authors:  Pramila Paudyal; Bishnuhari Paudyal; Hirofumi Hanaoka; Noboru Oriuchi; Yashuhiko Iida; Hiroki Yoshioka; Hideyuki Tominaga; Satoshi Watanabe; Shigeki Watanabe; Noriko S Ishioka; Keigo Endo
Journal:  Cancer Sci       Date:  2009-12-22       Impact factor: 6.716

5.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Authors:  David B Solit; Fuzhong F Zheng; Maria Drobnjak; Pamela N Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B Agus; Howard I Scher; Neal Rosen
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

6.  HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice.

Authors:  Fabio Corsi; Luisa Fiandra; Clara De Palma; Miriam Colombo; Serena Mazzucchelli; Paolo Verderio; Raffaele Allevi; Antonella Tosoni; Manuela Nebuloni; Emilio Clementi; Davide Prosperi
Journal:  ACS Nano       Date:  2011-08-01       Impact factor: 15.881

7.  Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference.

Authors:  Wee Beng Tan; Shan Jiang; Yong Zhang
Journal:  Biomaterials       Date:  2006-12-11       Impact factor: 12.479

Review 8.  Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression.

Authors:  Gang Niu; Weibo Cai; Xiaoyuan Chen
Journal:  Front Biosci       Date:  2008-01-01

9.  Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.

Authors:  Stig Palm; Richard M Enmon; Cornelia Matei; Katherine S Kolbert; Su Xu; Pat B Zanzonico; Ronald L Finn; Jason A Koutcher; Steven M Larson; George Sgouros
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

10.  A combinatorial library of an alpha-helical bacterial receptor domain.

Authors:  K Nord; J Nilsson; B Nilsson; M Uhlén; P A Nygren
Journal:  Protein Eng       Date:  1995-06
View more
  5 in total

Review 1.  Image-Guided Tumor Resection.

Authors:  Julia Parrish-Novak; Eric C Holland; James M Olson
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

2.  CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies.

Authors:  Sharat Srinivasula; Erin Gabriel; Insook Kim; Paula DeGrange; Alexis St Claire; Candace Mallow; Robert E Donahue; Chang Paik; H C Lane; Michele Di Mascio
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

3.  A Switchable Site-Specific Antibody Conjugate.

Authors:  Zhigang Lyu; Lei Kang; Zakey Yusuf Buuh; Dawei Jiang; Jeffrey C McGuth; Juanjuan Du; Haley L Wissler; Weibo Cai; Rongsheng E Wang
Journal:  ACS Chem Biol       Date:  2018-02-28       Impact factor: 5.100

Review 4.  Alternative reagents to antibodies in imaging applications.

Authors:  R Bedford; C Tiede; R Hughes; A Curd; M J McPherson; Michelle Peckham; Darren C Tomlinson
Journal:  Biophys Rev       Date:  2017-07-27

5.  Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.

Authors:  Anchal Ghai; Dolonchampa Maji; Nicholas Cho; Chantiya Chanswangphuwana; Michael Rettig; Duanwen Shen; John DiPersio; Walter Akers; Farrokh Dehdashti; Samuel Achilefu; Ravi Vij; Monica Shokeen
Journal:  J Nucl Med       Date:  2017-10-12       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.